Zydus Signs MRI Contrast Agent Licensing Deal With A Market Worth Of $237m
FDA And EMA Have Previously Scrutinized The Safety Of Gadolinium-Based Agents
Zydus bags two generic gadolinium-based contrasting agents in an exclusive licensing and supply agreement with Viwit, opening a new chapter of imaging injectables for the US market.
